COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,877 Articles (22,568 medRxiv, 8,309 bioRxiv)

Most recent first Previous |  Page 792: Articles 7911-7920  | Next

Economic vulnerability and poor service delivery made it more difficult for shack-dwellers to comply with COVID-19 restrictions: The impracticability and inequitable burden of universal/unstratified public health policies.
Ellison, G. T., Mattes, R. B., Rhoma, H., De Wet, T.
10.1101/2022.04.07.22273499 — Posted: 2022-04-12
Model evolution in SARS-CoV-2 spike protein sequences using a generative neural network
Kumar, A.
10.1101/2022.04.12.487999 — Posted: 2022-04-12
Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxis
Yogev, O., Weissbrod, O., Battistoni, G., Bressan, D., Naamti, A., Falciatori, I., Berkyurek, A. C., Rasnic, R., Hosmillo, M., Ilan, S., Grossman, I., McCormick, L., Honeycutt, C. C., Johnston, T., Gagne, M., Douek, D. C., Goodfellow, I., Hannon, G. J., Erlich, Y.
10.1101/2022.04.12.488010 — Posted: 2022-04-12
Discrimination of SARS-CoV-2 Omicron sub-lineages BA.1 and BA.2 using a high-resolution melting-based assay: A pilot study
Aoki, A., Adachi, H., Mori, Y., Ito, M., Sato, K., Okuda, K., Sakakibara, T., Okamoto, Y., Jinno, H.
10.1101/2022.04.11.487970 — Posted: 2022-04-12
The SARS-CoV-2 receptor-binding domain facilitates neutrophil transepithelial migration and nanoparticle uptake in the mice airways
Bolkhovitina, E. L., Vavilova, J. D., Bogorodskiy, A. O., Zagryadskaya, Y. A., Okhrimenko, I. S., Sapozhnikov, A. M., Borshchevskiy, V. I., Shevchenko, M. A.
10.1101/2022.04.12.488042 — Posted: 2022-04-12
Broadly neutralizing antibodies target the coronavirus fusion peptide
Dacon, C., Tucker, C., Peng, L., Lee, C.-C. D., Lin, T.-H., Yuan, M., Cong, Y., Wang, L., Purser, L., Williams, J. K., Pyo, C.-W., Kosik, I., Hu, Z., Zhao, M., Mohan, D., Cooper, A., Peterson, M., Skinner, J., Dixit, S., Kollins, E., Huzella, L., Perry, D., Byrum, R., Lembirik, S., Zhang, Y., Yang, E. S., Chen, M., Leung, K., Weinberg, R. S., Pegu, A., Geraghty, D., Davidson, E., Douagi, I., Moir, S., Yewdell, J. W., Schmaljohn, C., Crompton, P. D., Holbrook, M. R., Nemazee, D., Mascola, J. R., Wilson, I. A., Tan, J.
10.1101/2022.04.11.487879 — Posted: 2022-04-12
Hierarchical Computational Modeling and Dynamic Network Analysis of Allosteric Regulation in the SARS-CoV-2 Spike Omicron Trimer Structures: Omicron Mutations Cooperate to Allosterically Control Balance of Protein Stability and Conformational Adaptability
Verkhivker, G. M., Agajanian, S., Kassab, R., Krishnan, K.
10.1101/2022.04.11.487920 — Posted: 2022-04-12
A high potent synthetic nanobody with broad-spectrum activity neutralizes SARS-Cov-2 virus and Omicron variant through a unique binding mode
Huang, H., Li, S., Tao, Y., Xing, D., Xiong, H., Zhang, J., Li, L., Yang, X., Jiang, D., Luan, L., Lin, Y., Liu, X., Zheng, Q., Zhao, D., Xia, N., Liu, L.
10.1101/2022.04.11.487660 — Posted: 2022-04-12
An ACAT inhibitor regulates SARS-CoV-2 replication and antiviral T cell activity
Schmidt, N. M., Wing, P. A., Peters, R., Brown, R., Wang, H., Swadling, L., Newman, J., Thakur, N., Shionoya, K., Morgan, S. B., Hinks, T. S., Watashi, K., Bailey, D., Hansen, S. B., Maini, M. K., McKeating, J. A.
10.1101/2022.04.12.487988 — Posted: 2022-04-12
Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants
Chen, M., Pekosz, A., Villano, J., Shen, W., Zhou, R., Kulaga, H., Li, Z., Beck, S. E., Witwer, K. W., Mankowski, J., Ramanathan, M., Rowan, N., Lane, A.
10.1101/2022.04.12.487379 — Posted: 2022-04-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).